Fund Holdings — ARCH Venture Management, LLC

Total Portfolio Value
$651.68M
Total Bought
$12.03M
Total Sold
$114.0K
Net Transaction
+$11.92M
Filing Period:
Securities
▲▼
SharesValue ($K)
Q3 2025
▲▼
Q4 2025
▲▼
Change
▲▼
Q3 2025
▲▼
Q4 2025
▲▼
Weight (%)
▲▼
Change
▲▼
MAZE THERAPEUTICS INC.(MAZE)4,120,0534,120,0530106,833170,69426.19%+63,861
LYELL IMMUNOPHARMA INC.(LYEL)2,759,0722,759,072044,80784,92413.03%+40,117
ERASCA INC.(ERAS)11,055,55411,055,554024,10141,1276.31%+17,026
BEAM THERAPEUTICS INC.(BEAM)4,540,1324,540,1320110,189125,85219.31%+15,663
10X GENOMICS INC.(TXG)0737,539+737,539012,0291.85%+12,029
VIR BIOTECHNOLOGY INC.(VIR)12,916,66312,916,663073,75477,88711.95%+4,133
GOSSAMER BIO INC.(GOSS)8,055,9168,055,916021,18724,9733.83%+3,786
RAPPORT THERAPEUTICS INC.(RAPP)3,728,7383,728,7380110,744113,13017.36%+2,386
Q32 BIO INC.(FIXX)320,482320,48206351,0640.16%+429
CERO THERAPEUTICS HOLDINGS INC.22,3890-22,3891140—-114
Page 1 of 1
ARCH Venture Management, LLC — 13F Holdings — Q4 2025 | TickerTrail